Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02065365 2000-06-15
BOVINE CORONAVIRUS
POLYPEPTIDES AND VACCINES
Description
Technical Field
The present invention is directed to
vaccines to protect against coronavirus infection, with
particular usefulness in protecting cattle against bovine
coronavirus ("BCV"). The present invention is also
directed to the materials and methods for producing
coronavirus vaccines, as well as methods of using the
vaccines.
Background of the Invention
Coronaviruses were initially recognized as
a unique group based on their distinctive morphology. The
virions, when negatively stained, have large, petal-shaped
glycoprotein spikes or "peplomers." These spikes project
from the envelope of the virions. The name "coronavirus"
was suggested because of the virus' resemblance to the
corona spinarium, or crown of thorns, that surrounded the
heads of figures in medieval religious art.
Alternatively, the appearance of the projecting proteins
of the virion has been likened to the solar corona.
The coronaviruses cause diseases in humans
as well as in domestic and laboratory animals. Many of
WO 91/02752 PCT/CA90/00252
~C3'~ '.~~ ~~
_2_
these diseases are of great economic importance, often
causing severe enteric or respiratory infection in
animals. Characteristically, the coronaviruses which
cause enteric infections result in only mild or
inapparent infection in adult animals, but cause severe
diarrheal disease in newborn or infant animals.
The coronavirus has several structural
components. Its genomic RNA is a single plus strand
that is 16 to 21 kilobases long. The coronaviruses are
enveloped RNA viruses. Thus, the nucleocapsid lies
within a lipoprotein envelope. This envelope is derived
from either the rough endoplasmic reticulum or the Golgi
apparatus of infected cells. Within the lipid bilayer
of the envelope are other viral glycoproteins.
The coronaviruses comprise at least four
antigenic groups. These groups have been characterized
based on enzyme-linked immunoassays (ELISA), serologic
studies with immunofluorescence assays,
virus-neutralization tests, and immunoelectron
microscopy. Within each group, the viruses exhibit
partial antigenic cross-reactivity; they are, however
readily distinguished by their host specificity and
clinical syndromes.
Coronaviruses usually have three unique, major
structural proteins: N, E1, and E2. In addition, some
coronaviruses, such as bovine coronavirus, have a fourth
structural protein designated E3.
The N or nucleocapsid protein is a basic
phosphoprotein of 50 to 60K. Many copies of the N
protein combine with the genomic RNA to form a long,
flexible nucleocapsid having helical symmetry. The N
protein is the most abundant protein in the virion. The
WO 91 /02752 PCT/CA90/00252
-3-
N proteins of porcine transmissible gastroenteritis
virus (TGEV), mouse hepatitis virus (MHV), and avian
infectious bronchitis virus (IBV) show only about 27~
homology with each other.
The transmembrane or matrix protein,
designated E1 (or sometimes M), is often a group of
differently glycosylate~ proteins including a
nonglycosylated precursor. The E1 protein serves to
bind the nucleocapsid to the viral envelope as the virus
buds into the endoplasmic reticulum and Golgi apparatus
membranes. E1 may be phosphorylated on serine or
threonine residues rather than on asparagine as are most
other viral glycoproteins. Antibodies to E1 require the
presence of comp~zment to neutralize viral infectivity.
The peplomer protein, often designated E2, is
a glycoprotein that makes up the large "petal shaped"
surface projections of the virus. A small anchor of the
protein is embedded in the membrane, with most of the
molecule residing outside of the lipid bilayer. E2 has
an apparent molecular weight of 180 to 200 K. The E2
glycoprotein is involved in virus attachment, cell
membrane fusion, and virus-neutralizing antibody
production.
The E2 proteins of FIPV and the
closely-related TGEV differ from E2 of MHV and IBV in
two important respects. First, proteolytic cleavage of
° E2 is not required for activation; FIPV is effective in
inducing cell fusion. Second, the E2 of FIPV and TGEV
are larger (210K compared to 180K, with proteolytic
cleavage to two products of 80 to 90K required for cell
fusion activity in MHV). In addition, de Groot et al.,
(1987) Adv. EXD. Med. Biol. 218:31-38, report that the
WO 91/02752 PCT/CA90/00252
-4-
cloning and sequencing of the E2 genes of IBV M41, MHV
A59 and FIPV 79-1146 indicated that the E2 proteins have
low overall amino acid homology (with no~numerical
percentage given; regions were considered highly
homologous if two sequences were at least 30%
identical).
Infectious Bronchitis Virus (IBV) Avian:
Infectious bronchitis virus (IBV) avian is a
respiratory pathogen in fowl and therefore of great
economic importance to the poultry industry.
Background IBV (M41) E2 characterization may be found in
Cavanagh (1983), J. Gen. Virology 64:2577-2583.
Cavanagh et al., (1984) Avian Pathology
13:573-583, reported inoculating chickens with sucrose
gradient purified IHV proteins and then challenging the
inoculated birds with IBV. Although E2 (termed "S" for
spike by the Cavanagh lab) caused antibody production,
it was ineffective to impart IBV protection/resistance
to the inoculated chickens, as evidenced by their
susceptibility to the characteristic IBV respiratory
infection.
Mockett et al. (1984), J. Gen. Virology
65:2281-2286, have produced anti-E2 monoclonal
antibodies (MAbs) which neutralized only one strain of
IBV (M41) in vitro.
Tomley et al. (1987), J. Gen. Viroloc~y
68:2291-2298, have made a cDNA clone of IBV E2 and
inserted it into a vaccinia virus. The expressed
recombinant E2 protein was recognized by anti-E2
antisera. Mice were vaccinated with the recombinant
virus. The neutralization titers of inoculated mice,
WO 91/02752 PCT/CA90/00252
i~~~~"r3~~J
-5-
although higher than the controls, were, however, low.
(7 weeks after inoculation, mice injected with the
recombinant virus had a neutralization titer of 1:25'
against the test strain compared to 1:10 for sera from
mice inoculated with control (wild type vaccinia)
virus.)
According to one source, "excellent vaccines
are available for IBV" but "the disease is still
widespread due to the occurrence of new variants."
Niesters et al., (1986) Virus Research 5:253-263, at
261. The authors, therefore, synthesized cDNA clones,
reported the IHV M41 nucleotide sequence and compared
the predicted amino acid sequences of two IBV strains
(M41 and M42), which have different neutralization
epitopes in an attempt to localize the IBV neutralizing
epitopes. Niesters et al., (1986) supra, at 257, Fig.
2. The authors stated that "[s]o far as is known, only
antibodies directed against the S1 [portion] of the
peplomer protein are able to neutralize virus
2p infectivity." Niesters et al., supra, at 261. Tomley
et al., su ra, reiterated that no other viral proteins
are targets for antibody-mediated virus neutralization.
"Despite this [knowledge], protective immune responses
have not yet been obtained in birds inoculated with
purified spike protein." Tomley et al. at 2292.
Porcine Transmissible Gastroenteritis (TGEV)
Porcine transmissible gastroenteritis (TGEV)
causes neonatal viral enteritis. Infection is often
fatal for piglets under two weeks of age. TGEV, like
the murine and avian coronaviruses, has the three
polypeptides N, E1, and E2. Anti-E2 monoclonal
WO 91/02752 PCT/CA90/00252
-6-
antibodies were generated (using a concentrated crude
suspension of Purdue virus) and used in in vitro
neutralization assays. Laude et al. (1986), J. Gen.
yirology 67:119-130.
Mouse Hepatitis Virus (MHV)
Mouse hepatitis virus (MHV) is a neurotropic
virus which has been studied quite extensively; since it
causes demyelination, MHV is a possible model for such
diseases as multiple sclerosis. Sturman et al. (1985),
J. Virology 56:904-911, report that coronavirus
infection frequently results in cell fusion both in vivo
and in vitro. In vitro, the syncytia detach from the
substrate and die. Monospecific serum to E2 added to
cell cultures 2-4 hours after inoculation was shown to
"markedly inhibit" cell fusion. Furthermore, it was
reported that proteolytic cleavage of E2 may be required
to initiate or activate the cell-fusing activity of the
protein.
MHV-4, JHM strain is also reported to contain
the three major structural proteins N, E1, and E2.
Dalziel et al. (1986), J. Virology 59:463-471, at 463.
Dalziel et al, prepared anti-E2 MAbs and studied the
effect of mutation on virulence. Virus neutralization
by the MAbs was evaluated in vitro. Earlier work by
this laboratory, reported in Talbot et al., (1984),
Virology 132:250-260, identified four epitopes on E2,
two of which mediated virus neutralization in vitro.
Anti-E2 MAbs passively protected mice from lethal
challenge to intracerebral inoculation with MHV-4 in
vivo, although they still suffered demyelination.
Bachmeier et al. (1984), Virology 132:261-270. The
WO 91 /02752 PCT/CA90/00252
i4'~~J~~~J~
_7_
studies by Buchmeier et al. point out that in vitro
neutralization and in vivo protection are not
correlated. Buchmeier et al., supra, at 268, col. 1.
Infection of the central nervous system by MHV was not
prevented by those MAbs designated "protective."
Protection apparently was conferred by slowing of viral
replication, without stopping it. Id. In addition,
"protective" antibody, which protected against lethal
encephalitis, did not prevent demyelination by a MHV-4
temperature-sensitive mutant. Id. at 269, col. 1.
Wege et al. (1984), J. Gen. Virology
65:1931-1942, also studied the ability of anti-E2 MAbs
to protect rats from acute encephalomyelitis (Table 3,
at 1939). Wege et al. developed and analyzed monoclonal
antibodies against various epitopes of MHV E2 protein.
Some of the antibodies which inhibited cell fusion in
vitro were able to prevent rats from developing fatal
encephalomyelitis, although demyelination was not
eliminated but was merely reduced. Again, passive
protection against lethal challenge using MAbs to MI-iV E2
provides limited protection in the murine system as
shown by both Dalziel et al, su ra, and the Wege group.
Schmidt et al., (1987) J. Gen. Virology
68:47-56 have sequenced E2 and predicted the amino acid
sequence. The S2 subunit of E2, is presumed to remain
membrane-bound following proteolytic cleavage/cell-
fusing activation. This is somewhat similar to the S2
subunit of IBV. But see Makino et al. (1987), Proc.
Natl. Acad. Sci. 84:6567-6571, which report that the
carboxy terminal 1/3 of E2 is at least partially
responsible for MHV neuropathogenicity and
neutralization. Makino et al. postulate that cleavage
WO 91/02752 PCT/CA90/00252
;~:~~ 3rf'sJ
-8_ .
of the 180K E2 protein to 90K subunits, which activates
cell-fusion, may expose the carboxyl half of E2.
The field of coronavirus research has-been
principally directed to the murine virus system due to
the potential for understanding diseases of the nervous
system. In addition, research on the avian IBV and the
porcine TGEV have been of great interest to the poultry
and the swine industries, respectively. In these
non-BCV coronavirus systems, the development of vaccines
appears to have been limited to the poultry industry;
due to the development of new variants, however, IBV
disease is still widespread. Niesters et al., su ra.
Early studies have been done on eliciting passive
protection to MHV.
Bovine coronavirus (BCV) is an important virus
in the cattle industry. BCV research has been directed
to developing cell lines for production and isolation of
BCV from cell cultures. Dea et al. (1980), Am. J. Vet.
Res. 41:30-38. In addition, one research group has used
2p whole virus to produce antisera, identifying various
glycoproteins. King et al. (1982), J. Virology
42:700-707; Hogue et al. (1984), J. Virology 51:384-388;
King et al. (1985), Virus Research 2:53-59. This group
has also mapped the BCV Mebus strain genes which encode
N and E1 (called "M" for matrix). Lapps et al., (1987)
Virology 157:47-57. Hogue et al., (1984), su ra used
immunoblots to identify a gp140 (glycoprotein having
molecular weight of 140K) composed of disulfide-linked
65K subunits. King et al., (1985), supra have also
reported a 140K glycoprotein, which is a
disulfide-linked dimer of two 65K glycoproteins, which
they state is the hemagglutinating protein of BCV.
WO 91 /02752 PCT/CA90/00252
~~~6J
_g_
Other than its function as a hemagglutinin, its role in
BCV repl~ation and pathogenesis are reported as
unknown. The glycoproteins identified by this group
have not been confirmed or reproduced by other groups.
The proteins identified could be fragments or artifacts
of the various native BCV proteins. Development of BCV
vaccines has not been reported.
The BCV E2 glycoprotein has an apparent
molecular weight of 190K which may presumably be cleaved
to two comigrating 100K proteins. The precursor to E2
is a 170K glycoprotein. This 170K precursor appears to
be further glycosylated to yield the 190K E2 (Deregt, D.
and Babiuk, L. (1987) Virology 161:410-420).
E3 is unique to certain coronaviruses. These
include bovine coronavirus, the hemagglutinating
encephalomyelitis virus (HEV) of swine, and the human
respiratory coronavirus (HCV-OC43). See, e.4., Parker
et al. (1989) J. Gen. Virol. 70:155-64.
An ideal BCV vaccine would have the ability to
protect or ameliorate pathogenesis without the risk of
infection, a risk Which exists with a live or whole
virus vaccine.
Disclosure of the Invention
In the present invention, it has been
discovered that HCV has, in addition to the E2 protein,
a protein designated "E3." Recombinant BCV polypeptides
have been produced from cloned E2 and E3 genes. The E2
and E3 genes have been sequenced and the amino acid
sequence of the primary translation product of these
genes has been predicted. The BCV E2 and E3
glycoproteins, particularly the recombinant form of
WO 91 /02752 PCT/CA90/00252
2C,~~~~~~~
-lo-
these proteins, have been identified as important
immunological targets and therefore useful as components
of a vaccine directed toward preventing BCV infection in
bovine populations. The recombinant E2 and E3 of the
present invention are very effective subunit antigens
for a vaccine composition. Further, clones which
represent the entire BCV genome have been construcr.ed
and the E2 and E3 gene sequences have been identified.
The present invention, therefore, has several
embodiments. In particular, the invention is directed
to a DNA molecule comprising a coding sequence for BCV
protein or antigenic fragments thereof, wherein the BCV
protein is selected from the group consisting of E2 and
E3. Identification of antigenic fragments is within the
skill of the art in view of the disclosure herein and
includes, for example, producing trypsin fragments,
short oligopeptides, etc., and using standard methods to
screen the fragments produced for antigenicity and other
activity. The DNA molecule may further comprise an
2p expression cassette comprising the above coding sequence
and control sequences operably linked to the coding
sequence whereby the coding sequence can be transcribed
and translated in a host cell, wherein at least one of
the control sequences is heterologous to the coding
sequence. The coding sequence may encode substantially
complete BCV protein, such as E2 and/or E3, or antigenic
fragments of E2 and/or E3.
The present invention is also directed to host
cells comprising this DNA molecule, as well as methods
of producing recombinant polypeptides comprising an
antigenic BCV E2 or E3 sequences.
WO 91 /02752 PCT/CA90/00252
-11-
In another embodiment, the present invention
is directed to a method of eliciting an .immune response
in a mammalian host against BCV infection comprising:
(a) providing a vaccine composition comprising a
pharmaceutically acceptable carrier and at least one
subunit antigen comprising an antigenic BCV polypeptide
selected from the group consisting of E2, E3, and
antigenic fragments thereof; and (b) administering to
the mammalian host an amount of the vaccine composition
effective to elicit an immune response.
In yet another embodiment of the present
invention, a vaccine composition for (BCV) is provided
comprising a pharmaceutically acceptable vehicle and an
effective amount of antigenic HCV polypeptide.
Yet another embodiment of the present
invention is a composition comprising substantially pure
Bovine Coronavirus (BCV) polypeptide or antigenic
fragments thereof wherein the BCV protein is selected
from the group consisting of E2 and E3.
The following disclosure will render these and
other embodiments of the present invention readily
apparent to those of skill in the art.
Brief Description of the Drawings
FIG. 1 is a schematic genetic map of BCV
structural protein genes. Approximately 10,000
nucleotides of the viral genome are represented in the
figure. The length of the reading frame of each gene is
indicated in nucleotides with the number of nucleotides
appearing below the name for each gene. The length of
the BCV N gene and 3' non-coding region are from Lapps
et al. Also shown is pCVAl2 probe homologous to the 3'
WO 91/02752 PCT/CA90/00252
~~~ ~'3.'~3 ~y~ J
-12-
end of the viral genome with 5' portion of pCVAl2 used
to identify clones extending into the E2 gene.
FIG. 2 shows a Northern blot analysis of BCv
RNA.
FIG. 3 shows the BCV E2 gene nucleotide
sequence and the predicted amino acid sequence of the E2
precursor protein. Reference numbers for the
polynucleotides are located above the sequence with
asterisks used to indicate the precise positioning of
the nucleotide corresponding to the reference number.
Reference numbers for the amino acid sequence appear at
the right-hand side end of each line. The conserved
intergenic sequence is surrounded by a rectangle; the
amino-terminal signal sequence is underscored with a
solid line; the carboxy-terminal transmembrane domain is
underscored with a discontinuous line; an arrow
indicates a probable site of precursor cleavage, and
potential N-linked glycosylation sites are indicated by
solid circles.
FIG. 4 shows the BCV E3 gene nucleotide
sequence and the predicted amino acid sequence of the
primary translation product. Reference numbers for the
polynucleotides are located above the sequence with
asterisks used to indicate the precise position of the
nucleotide corresponding to the reference number.
Reference numbers for the amino acid sequence appear at
the right-hand side end of each line. The conserved
intergenic sequence is surrounded by a rectangle; the
amino-terminal signal sequence is underscored with a
solid line; the carboxy-terminal transmembrane domain is
underscored with a solid line passing through open
WO 91/02752 PCT/CA90/00252
-13-
circles, and potential N-linked glycosylation sites are
indicated by solid circles.
FIG. 5 is a photograph of an SDS-PAGE -gel on
which proteins produced by in vitro translation of mRNA
produced from BCV E2 and E3 genes subcloned into plasmid
(pTZ 19R) are analyzed. Below the photograph are lane
numbers, to the right hand side of the photograph are
numbers indicating molecular weights. Lane 1, E2 gene
product; lane 2, molecular weight markers; lane 3, E3
gene products; lane 4, E3 gene products synthesized in
the presence of pancreatic microsomes. MW, molecular
weights x 10-3.
FIG. 6 is a photograph of a PAGE gel which
shows expression of the BCV E3 polypeptide in
AcNPV-infected insect cells. Lanes are indicated across
the top by capital letters; molecular weights (x 10-3)
are vertical along the lefthand side of the figure.
FIG. 7 is a photograph of a PAGE gel which
shows synthesis of the BCV E2 polypeptide by recombinant
2p baculovirus in S. fruQiperda cells. Lanes are
indicated across the top by numbers; panels are
indicated below by capital letters. Molecular weights
(x -3) are indicated at the left of the figure.
FIG. 8 is a comparison of the amino acid
sequence homology between E2 glycoproteins of bovine
coronavirus and murine hepatitis virus strains JF~t and
A59. (JHIrt from Schmidt et al. (1987) J. General
Virolocty 68:47-56; A59 is from deGroot et al. (1987)
Adv. Exp. Med. Biol. 218:31-38.)
WO 91 /02752 PCT/CA90/00252
~~,~~~~~~J
-14-
Modes of Carrying Out the Invention
The practice of the present invention will
employ, unless otherwise indicated, conventional
microbiology, virology, molecular biology, and
recombinant DNA techniques which are within the skill of
the art. These techniques are fully explained in the
literature. See, e.g., Maniatis et al., Molecular
Cloning: A Laboratory Manual (1982); DNA Cloning: A
Practical Approach, vols. I & II (D. Glover, ed.);
Oligonucleotide Synthesis (N. Gait, ed. (19841); Nucleic
Acid Hybridization (B. Hames & S. Higgins, eds. (1985));
Transcription and Translation (B. Hames & S. Higgins,
eds. (1984)); Animal Cell Culture (R. Freshney, ed.
(1986)); Perbal, A Practical Guide to Molecular Cloning
(1984).
A. Definitions
In describing the present invention, the
following terminology, as defined below, will be used.
A "replicon" is any genetic element (e-g.,
plasmid, chromosome, virus) that functions as an
autonomous unit of DNA replication in vivo; i.e., is
capable of replication under its own control.
A "vector" is a replicon, such as a plasmid,
phage, or cosmid, to which another DNA segment may be
attached so as to bring about the replication of the
attached segment.
A "double-stranded DNA molecule" refers to the
polymeric form of deoxyribonucleotides (adenine,
guanine, thymine, or cytosine) in its normal,
double-stranded helix. This term refers only to the
primary and secondary structure of the molecule, and
WO 91/02752 PCT/CA90/00252
~~5~~~6
-15-
does not limit it to any particular tertiary forms.
Thus, this term includes double-stranded DNA found,
inter alia, in linear DNA molecules (e.4., restriction
fragments), viruses, plasmids, and chromosomes. In
discussing the structure of particular double-stranded
DNA molecules, sequences may be described herein
according to the normal convention of giving only the
sequence in the 5' to 3' direction along the
nontranscribed strand of DNA (i.e., the strand having
the sequence homologous to the mRNA).
A DNA "coding sequence" is a DNA sequence
which is transcribed and translated into a polypeptide
in vivo when placed under the control of appropriate
regulatory sequences. The boundaries of the coding
sequence are determined by a start codon at the 5'
(amino) terminus and a translation stop codon at the 3'
(carboxy) terminus. A coding sequence can include, but
is not limited to, procaryotic sequences, cDNA from
eucaryotic mRNA, genomic DNA sequences from eucaryotic
(e-4., mammalian) DNA, and even synthetic DNA sequences.
A polyadenylation signal and transcription termination
sequence will usually be located 3' to the coding
sequence.
A "promoter sequence" is a DNA regulatory
region capable of binding RNA polymerase in a cell and
initiating transcription of a downstream (3' direction)
coding sequence. For purposes of defining the present
invention, the promoter sequence is bound at the 3'
terminus by the translation start codon (ATG) of a
coding sequence and extends upstream (5' direction) to
include the minimum number of bases or elements
necessary to initiate transcription at levels detectable
WO 91/02752 PCT/CA90/00252
-16-
above background. Within the promoter sequence will be
found a transcription initiation site (conveniently
defined by mapping with nuclease S1), as well as protein
binding domains (consensus sequences) responsible for
the binding of RNA polymerase. Eucaryotic promoters
will often, but not always, contain "TATA" boxes and
"CAT" boxes. Procaryotic promoters contain
Shine-Dalgarno sequences in addition to the -10 and -35
consensus sequences.
DNA "control sequences" refer collectively to
promoter sequences, ribosome binding sites,
polyadenylation signals, transcription termination
sequences, upstream regulatory domains, enhancers, and
the like, which collectively provide for the
transcription and translation of a coding sequence in a
host cell.
A coding sequence is "operably linked to" or
"under the control of" control sequences in a cell when
RNA polymerase will bind the promoter sequence and
transcribe the coding sequence into mRNA, which is then
translated into the polypeptide encoded by the coding
sequence.
A "host cell" is a cell which has been
transformed, or is capable of transformation, by an
exogenous DNA sequence.
A cell has been "transformed" by exogenous DNA
when such exogenous DNA has been introduced inside the
cell membrane. Exogenous DNA may or may not be
integrated (covalently linked) to chromosomal DNA making
up the genome of the cell. In procaryotes and yeasts,
for example, the exogenous DNA may be maintained on an
episomal element, such as a plasmid. A stably
WO 91 /02752 PCT/CA90/00252
i~~~~~~~ :a
-17-
transformed cell is one in which the exogenous DNA has
become integrated into the chromosome so that it is
inherited by daughter cells through chromosome
replication. For mammalian cells, this stability is
demonstrated by the ability of the cell to establish
cell lines or clones comprised of a population of
daughter cell containing the exogenous DNA.
A "clone" is a population of daughter cells
derived from a single cell or common ancestor. A "cell
line" is a clone of a primary cell that is capable of
stable growth in vitro for many generations.
Two polypeptide sequences are "substantially
homologous" when at least about 80% (preferably at least
about 90%, and most preferably at least about 95%) of
the amino acids match over a defined length of the
molecule.
Two DNA sequences are "substantially
homologous " when they are identical to or not differing
in more that 40% of the nucleotides, more preferably
about 20% of the nucleotides, and most preferably about
10% of the nucleotides.
DNA sequences that are substantially
homologous can be identified in a Southern hybridization
experiment under, for example, stringent conditions, as
defined for that particular system. Defining
appropriate hybridization conditions is within the skill
of the art. See, e.4., Maniatis et al., supra; DNA
~loning, vols. I & II, supra; Nucleic Acid
Hybridization, supra.
A "heterologous" region of a DNA construct is
an identifiable segment of DNA within or attached to
another DNA molecule that is not found in association
WO 91 /02752 PCT/CA90/00252
~~?~W' ~ i
-18-
with the other molecule in nature. Thus, when the
heterologous region encodes a viral gene, the gene will
usually be flanked by DNA that does not~flank the viral
gene in the genome of the source virus or virus -infected
cells. Another example of the heterologous coding
sequence is a construct where the coding sequence itself
is not found in nature (e. Q., synthetic sequences having
codons different from the native gene). Allelic
variation or naturally occurring mutational events do
not give rise to a heterologous region of DNA, as used
herein.
"Bovine host" refers to cattle of any breed.
The term "protein" or "glycoprotein" is used
herein to designate a polypeptide or glycosylated
polypeptide, respectively. The term "polypeptide" is
used in its broadest sense, i.e., any polymer of amino
acids (dipeptide or greater) linked through peptide
bonds. Thus, the term "polypeptide" includes proteins,
oligopeptides, protein fragments, analogs, muteins,
fusion proteins and the like.
"Fusion protein" is usually defined as the
expression product of a gene comprising a first region
encoding a leader sequence or a stabilizing polypeptide,
and a second region encoding a heterologous protein. It
involves a polypeptide comprising an antigenic protein
fragment or a full length BCV protein sequence as well
as (a) heterologous sequence(s), typically a leader
sequence functional for secretion in a recombinant host
for intracellularly expressed polypeptide, or an
N-terminal sequence that protects the protein from host
cell proteases, such as SOD. An antigenic protein
fragment is usually about 5-7 amino acids in length.
"~O 91 /02752 ~ ~ ~ ~ ~ ~ J PCT/CA90/00252
-19-
"Native" proteins or polypeptides refer to
proteins or polypeptides recovered from BCV or
BCV-infected cells. Thus, the term "native BCV.
polypeptide" would include naturally occurring BCV
proteins and fragments thereof. "Non-native"
polypeptides refer to polypeptides that have been
produced by recombinant DNA methods or by direct
synthesis. "Recombinant" polypeptides refers to
polypeptides produced by recombinant DNA techniques;
i.e., produced from cells transformed by an exogenous
DNA construct encoding the desired polypeptide.
"BCV protein" means a polypeptide having a
sequence substantially homologous to a native BCV
protein.
A "substantially pure" BCV protein will be
free of other BCV proteins, preferably at least 10%
homogeneous, more preferably 60% homogeneous, and most
preferably 95% homogeneous.
A "subunit antigen" is an antigen separate
from a whole virus or virus-infected cell. For example
a subunit antigen may be a recombinant protein and, in
the preferred embodiment, can also comprise naturally
occurring antigen isolated from whole virus, virus
lysate, or infected cells.
B. General Method
Bovine Coronavirus (BCV) is a well-known
virus, and has a single-stranded, nonsegmented,
polyadenylated RNA genome of approximately 20 kb (Lapps
et al., (1987) Virology 157:47-57). BCV is composed of
the proteins N, E1, and E2. In addition, it has been
discovered that BCV has a fourth structural protein,
WO 91 /02752 PCT/CA90/00252
r
i~r ~, ~J..~. ~a vt ~~.7
-20-
designated E3, which has now been cloned and
characterized. Particularly important to the present
invention are the E2 and E3 genes and the proteins that
these genes encode.
The E3 glycoprotein is a disulfide-linked
dimer having an apparent molecular weight of 124K. The
precursors to E3 are primarily a 59K glycoprotein
monomer which undergoes rapid dimerization to produce a
118K dimer. The 118K glycoprotein dimer undergoes
further glycosylation to produce the 124K E3 (Deregt, D.
and Babiuk, L. su ra).
The reading frame of the E2 gene is 4089
nucleotides long and encodes a polypeptide of 1363 amino
acids. The E3 gene is immediately 5' of the E2 gene on
the viral genome and contains an open reading frame of
1272 nucleotides and encodes a polypeptide of 424 amino
acids. The E3 gene terminates 14 nucleotides upstream
from the E2 polypeptide initiation codon. The
nucleotide sequence and predicted amino acid sequences
of E2 and E3 are shown in FIGS. 3 and 4, respectively.
The present invention provides, inter alia, a
subunit antigen useful in producing BCV vaccines.
BCV polypeptides from E2 and/or E3 are the
subunit antigens in the present invention. Polypeptide
subunit antigens are generally at least about 5 amino
acids in length so as to encode an epitope, but are
preferably at least about 10-15 amino acids in length.
Typically, the antigens are about 20 or more amino acids
in length. It is believed that no critical upper limit
to the subunit antigen length exists. Thus, the subunit
antigen can comprise an entire viral protein sequence,
WO 91/02752 PCT/CA90/00252
r~C~~'3~.36!~
-21-
or even a fusion protein comprising the sequences of two
or more of the viral glycoproteins. _
The subunit antigens of the present invention
can be either native E2 or E3 glycoproteins, fragments
thereof, or recombinant E2 or E3 polypeptides. The
recombinant subunits can be partial glycoprotein
sequences, full-length protein sequences, or even fusion
proteins (e.a., having appropriate leader sequences for
the recombinant host, or with an additional subunit
antigen sequence for BCV or another pathogen). Although
the subunit antigen has epitopes derived from
glycoproteins, it need not be glycosylated.
The preferred subunit glycoproteins of the
present invention contain full-length (or near
full-length) sequences of E2 or E3. Alternatively,
shorter sequences that are antigenic (i.e., encode one
or more epitopes) can be used. The shorter sequence may
encode a "neutralizing epitope," which is defined as an
epitope capable of eliciting antibodies that neutralize
virus infectivity in an in vitro assay. Preferably the
peptide should encode a "protective epitope" that is
capable of raising in the host an "immune response;"
i.e., either an antibody- or a cell-mediated response
that protects an immunized host from infection or
ameliorates the course of disease.
The subunit antigens of the present invention,
particularly when comprised of short oligopeptides, may
be conjugated to a vaccine carrier. Vaccine carriers
are well known in the a:-t: for example, bovine serum
albumin (BSA), human serum albumin (HSA) and keyhole
limpet hemocyanin (KLH>. A preferred carrier protein,
206 5365
-22-
rotavirus VP6, is disclosed in EPO Pub. No. 0259149.
The polypeptides encoding BCV epitopes of the
present invention may also be incorporated within
particle-forming viral polypeptides as a fusion protein,
as described in U.S. Pat. No. 4,722,840 and EPO Pub. No.
174,759. Alternatively, the BCV subunit antigens of the
present invention can be incorporated into a foreign
virus (e.Q., vaccinia or adenovirus) as is known in the
art.
Also within the skill in the art is to
formulate the subunit antigen(s), with or without
carriers, into a vaccine composition comprising a
pharmaceutically acceptable vehicle and, if desired, an
adjuvant. These formulations are preferably adapted for
intramuscular injection, since intravenous injection is
not usually practical for large-scale inoculation of
domestic animals.
Vehicles useful for parenteral injection are
usually nontoxic and nontherapeutic. Such vehicles
include water, saline solution, Ringer's solution,
dextrose solution, and Hanks' solution, Nonaqueous
vehicles, such as fixed oils, sesame oil, ethyl oleate,
or triglycerides may also be used. Suspensions
containing viscosity-enhancing agents such as sodium
carboxymethylcellulose, sorbitol, or dextran may also be
used. In addition, the vehicle usually will contain
additives, for example to enhance isotonicity and
chemical stability. Useful buffers include phosphate
buffer, bicarbonate buffer, and TRIS buffer.
Preservatives can include thimerosal, m- or o-cresol,
formalin, and benzyl alcohol. Standard formulations are
WO 91 /02752 :2
X206 5365
-23-
generally liquid injectables or solids capable of being
dissolved in solution or suspended in a_suitable liquid
before injection. In a nonliquid formulation,
therefore, the vehicle may comprise dextrose, bovine _
serum albumin, preservatives, etc., to which sterile
water or saline are added before administration.
Also known within the art are adjuvants useful
in the vaccine formulations of the present invention.
Selecting the appropriate adjuvant and determining its
Proper concentration in the vaccine compositions) of
the present invention is also within the skill of the
art. Adjuvants may include Freund's, aluminum salts,
[A1(OH)3, A1P04, A12(S04)g], Ca3(P04)2, muramyl di- and
tri-peptides, saponin, DDA, Pluronics, oil-in-water
emulsions (containing, e.4., dextran sulphate or vitamin
E) and water-in-oil emulsions (containing, e.Q.,
polysorbate 80).
The vaccines may also be orally administered
with the subunits in a suitable oral carrier. Oral
formulations include such normally-employed excipients
as, for example, pharmaceutical grades of mannitol,
lactose, starch, magnesium stearate, sodium saccharin
cellulose, magnesium carbonate, and the like. Oral
vaccine compositions may be taken in the form of
solutions, suspensions, tablets, pills, capsules,
a sustained release formulations, or powders, containing
from about 10% to about 95% of the active ingredient,
preferably about 25% to about 70%. An oral BCV vaccine
may be preferable to raise mucosal immunity in
combination with systemic immunity raised by
intramuscular administration of the vaccine.
WO 91/02752 PCT/CA90/00252
~ r-~ ~) ~C.' r-.
~C.~S~~~~
-24-
In addition, the vaccine may be formulated
into a suppository. For suppositories, the vaccine
composition will include traditional binders and.
carriers, such as polyalkaline glycols or triglycerides.
Such suppositories may be formed from mixtures
containing the active ingredient in the range of about
0.5% to about 10% (w/w), preferably about 1% to about
2%.
Protocols for administering to animals the
vaccine compositions) of the present invention are
within the skill of the art in view of the present
disclosure. Those skilled in the art will select a
concentration of subunit antigens) in the vaccine
composition in a dose effective to elicit an antibody
and/or T-cell response to the antigenic fragment.
Within wide limits, the dosage is not believed to be
critical. Typically, the vaccine composition is
administered in a manner which will deliver between
about 1 to about 1,000 micrograms of the subunit antigen
in a convenient volume of vehicle, e.a., about 1-10 cc.
Preferably, the dosage in a single immunization will
deliver from about 1 to about 500 micrograms of subunit
antigen, more preferably about 5-10 to about 100-200
micrograms (e-Q., 5-200 micrograms).
The timing of administration may also be
important. For example, a primary inoculation
preferably may be followed by subsequent booster
inoculations. It may also be preferred, although
optional, to administer a second, booster immunization
to the animal several weeks to several months after the
initial immunization. To insure sustained high levels
of protection against disease, it may be helpful to
WO 91/02752 PCT/CA90/00252
-25-
readminister a booster immunization to the animals at
regular intervals, for example once every several years.
Alternatively, an initial dose may be administered
orally followed by later inoculations, or vice versa.
Preferred vaccination protocols can be established
through routine vaccination protocol experiments.
The subunit antigen can be produced from
protein recovered from virus or virus-infected cells.
For example, purified virus or virus-infected cells can
be disrupted or lysed and subjected to immunoadsorbent
chromatography to purify E1 or E2. The production of
monoclonal antibodies is within the skill of the art.
Briefly, a mammal, such as a mouse, is immunized with
either purified virus or the purified viral glycoprotein
of interest (e. Q., SDS-PAGE purified) and antibody-
producing B lymphocytes recovered. Typically, these B
lymphocytes are then fused with a continuous cell line
to produce an immortal antibody-producing cell line;
i.e., a hybridoma, trioma, etc. Immortal, antibody-
producing cell lines can also be created by techniques
other than fusion, such as direct transformation of B
lymphocytes with oncogenic DNA, or transfection with
Epstein-Barr virus. See, e.Q., M. Schreier et al.,
Hvbridoma Techniyues (1980); Hammerling et al.,
Monoclonal Antibodies and T-Cell Hybridomas (1981);
Kennett et al., Monoclonal Antibodies (1980); see also
U.S. Pat. Nos. 4,341,761; 4,399,121; 4,427,783;
4,444,887; 4,451,570; 4,466,917; 4,472,500; 4,491,632;
4,493,890. Native BCV proteins which are immunopurified
can be used in their entirety as subunit antigens, or
fragments of the entire proteins containing the
WO 91 /02752 PCT/CA90/00252
,~~~~~o ~c' S
-26-
neutralizing epitopes can be employed as subunit
antigens.
Non-native BCV polypeptides can be produced by
a number of methods. For example, oligopeptides
containing neutralizing epitopes can be prepared
synthetically by known techniques. See, e.g., U.S. Pat.
No. 4,735,896. It is preferred, however, to prepare the
non-native polypeptide subunit antigens by recombinant
DNA methods.
Recombinant polypeptide subunit antigens are
produced according to the present invention by
constructing an expression cassette and transforming a
host cell therewith to provide a cell line or culture
capable of expressing the subunit antigen which is
encoded within the expression cassette. The first step
in constructing the expression cassette is to obtain a
coding sequence for the glycoprotein or glycoprotein
epitopes of interest. Coding sequences for E2 and E3
are shown in FIGS. 3 and 4. Thus, coding sequences can
either be prepared directly by synthetic methods based
on the disclosed sequence (or equivalent sequences
encoding the same amino acids), or by using the
disclosed sequence to design oligonucleotide probes to
clone coding sequence using known techniques. The
coding sequence can be comprised entirely of BCV
glycoprotein-encoding sequences, or such glycoprotein
sequences can be fused to other sequence (e.4., leader
sequences) so that a fusion protein is encoded. See,
e-q., U.S. Pat. Nos. 4,431,739; 4,425,437; 4,338,397.
Synthetic coding sequences will also allow for the
convenient construction of coding sequences which
express BCV glycoprotein analogs or "muteins."
WO 91/02752 PCT/CA90/00252
~~~5~~5
_2~_
Alternatively, coding sequences for muteins can be
prepared by site-directed mutagenesis of native BCv
nucleotide sequences. The techniques of site-directed
mutagenesis are known in the general art.
Once an appropriate coding sequence for the
subunit antigen has been prepared or isolated, it can be
cloned into any suitable vector or replicon. Numerous
cloning vectors or replicons are known to those of skill
in the general art, and the selection of an appropriate
cloning vector is a matter of choice. Examples of
recombinant DNA vectors for cloning and host cells which
can be transformed include various bacteriophage lambda
vectors (E. coli), pBR322 (E. coli), pACYC171 (E. coli),
pKT230 (gram-negative bacteria), pGV1106 (gram-negative
bacteria), pLAFRl (gram-negative bacteria), pME290
(non-E. coli gram-negative bacteria), pHVl4 (E. coli and
Bacillis subtilis), pBD9 (Hacillis), pIJ61
(Streptomyces), pUC6 (StreDtomyces), actinophage dC31
(Stre~tomyces), YIpS (Saccharomyces), YCpl9
(Saccharomyces), 2-micron plasmid (Saccharomvces), and
bovine papilloma virus (mammalian cells). See,
generally, DNA Cloning, vols. I & II, supra; Maniatis et
al., supra; Perbal, supra.
To complete construction of expression cas-
settes, the coding sequence as described above for the
subunit antigens is then operably linked to control
sequences (e-a., a promoter, etc.), so that the DNA
sequence encoding the subunit antigen is transcribed
into messenger RNA in the host cell transformed by the
expression cassette. In general, the coding sequence
will be downstream from the promoter sequence and any
expression regulatory regions, such as enhancers or
WO 91/02752 PCT/CA90/00252
~~~ '~.~'~a~~,3J
-28-
operator sequence. If the subunit antigen coding
sequence is linked to a heterologous coding sequence or
start codon, then it is important to place the subunit
antigen coding sequence in reading frame with the
latter. If the intended expression host is procaryotic,
then it will also be necessary to include a ribosome
binding site among the upstream control sequences.
Downstream operably linked control sequences will
usually comprise a transcription termination sequence,
and a polyadenylation signal (for mammalian expression
hosts).
When the intended expression host is a
procaryotic or yeast cell, the promoter and other
control sequences will necessarily be heterologous to
the subunit antigen coding sequence. If the selected
expression host cell is a mammalian cell, the control
sequences can be homologous BCV sequences, or preferably
heterologous mammalian control sequences. The
expression cassette can be constructed, for example, as
a discrete molecular entity flanked by convenient
restriction sites, or it can be constructed by inserting
the coding sequence into a previously constructed
expression vector with an appropriate insertion site.
A number of procaryotic expression vectors are
known. See, e.4., U.S. Pat. Nos. 4,440,859; 4,436,815;
4,431,740; 4,431,739; 4,428,941; 4,425,437; 4,418,149;
4,411,994; 4,366,246; 4,342,832; see also U.K.
Publication Nos. GB2,121,054; GB2,008,123; GB2,007,675;
and European Publication No. 103,395. The preferred
procaryotic expression vectors are those for E. coli.
Other preferred expression vectors are those for use in
eucaryotic systems. Yeast expression vectors are also
WO 91/02752 PCT/CA90/00252
-29-
known. See, e.g., U.S. Pat. Nos. 4,446,235; 4,443,539;
4,430,428; see also European Publication Nos. 103,409;
100;561; 96,491.
Preferred expression hosts of the present
invention are mammalian cells. Various cell lines and
expression vectors are known in the art. Examples of
appropriate mammalian expression hosts include kidney
cell lines (e'g., Madin Darby bovine kidney and CV-1
monkey kidney cell lines), fibroblast cell lines (e. a.,
h~an, murine or chicken embryo fibroblast cell lines),
Chinese hamster ovary (CHO) cells, HeLa cells, mouse
NIH/3T3 and/or LMTK- cells. It is also known to express
heterologous proteins in myeloma cell lines employing
immunoglobulin promoters. See, e.g., Banerji et al.
(1983), Cell 33:729-740; U.S. Pat. No. 4,663,281. The
selection of a mammalian cell line is not critical.
Various mammalian expression vectors employing viral
promoters (e. q,, SV40 early region promoter, Rous
sarcoma virus, LTR promoter, etc.) are also well known
in the art. See, e.g., Gorman et al. (1982), Proc.
Natl. Acad. Sci. USA 79:6777-6781; Southern et al.
(1982), J. Mol. App Genet 1:327-341; PCT Publication
No. W087/02062. Preferred eucaryotic expression vectors
are those employing the vaccinia virus, the SV40 virus,
or the Rous sarcoma virus. _See, e.g., Mackett et al.
(1984), J. Virol. 49:857; DNA Cloning, vol. II, pp,
191-211, supra; PCT Publication No. W086/07593;
Chakrabarty et al. (1985), Mol. Cell. Biol. _5:3403.
Another preferred embodiment of the present
invention is the expression of recombinant 3CV poly-
peptides in insect cells using viral vectors, such as
baculovirus. For example, high levels of expression
WO 91/02752 PCT/CA90/OOZ52
-30-
have been achieved with vectors based on Autoarapha
californica nuclear polyhedrosis virus (AcNPV) in
Spodoptera fruQiperda cells. See, e.Q., Smith et al.
(1983), J. Virol. 46:584-593; EPO Pub. No. 0259149,
supra.
Generally, a host cell which has been stably
transformed by an expression cassette for the subunit
antigen is selected to produce the recombinant poly-
peptide. A stably transformed host is one wherein the
expression cassette has integrated into the host cell's
chromosome. Alternatively, in the case of bacteria or
yeast expression hosts, it may be preferred to select
expression hosts that do not integrate the expression
cassette but maintain the cassette on a nonintegrating
ePisomal element, such as a plasmid. The subunit
antigen is produced by growing host cells transformed by
the expression cassette under conditions which cause the
expression of biologically active subunit antigen
polypeptide. The appropriate conditions to bring about
expression are well known in the art, and will depend
primarily on the expression system and host selected.
The subunit antigen polypeptide may be isolated from the
host cells and purified. If the expression system
secretes the subunit antigen, then the polypeptide can
be purified directly from the growth media. If subunit
antigen is not secreted, however, it may be necessary to
disrupt the host cells and purify the subunit antigen
polypeptide from the cellular lysate. Various purifi-
cation techniques, such as SDS-PAGE, HPLC and
immunoaffinity chromatography, are known, and the
selection of the appropriate purification and recovery
method is within the skill of the art.
206 5365
-31-
Described below are examples of the present
invention. These examples are provided only for
illustrative purposes and are not intended to limit the
scope of the present invention in any way. In light of
the present disclosure, numerous embodiments within the
scope of the claims will be apparent to those of
ordinary skill in the art.
C. Examples
Molecular Cloning of the BCV Genome
The Quebec isolate of bovine coronavirus (Dea
et al., (1980) Amer. J. Vet. Res. 41:30-38) was
propagated in Madin-Darby bovine kidney (MDBK) cells and
purified by polyethylene glycol precipitation and
sucrose gradient centrifugation as described previously
(Deregt et al., (1987) J. Gen Virol. 68:2863-2877).
Genomic RNA was prepared by phenol: chloroform:isoamyl
alcohol (50:48:2) extraction and ethanol precipitation.
Oligo-dT primed synthesis of double-stranded cDNA was
carried out by standard methods (Gubler et al., su ra
and Maniatis et al., su ra). After addition of BamHI
linkers, the double-stranded cDNA was fractionated by
electrophoresis on Tris-borate buffered 1~ agarose gels
and cDNA of greater than 3000 nucleotide by pairs was
ligated to BamHI-cleaved pTZ 19R multi-functional
plasmid (Pharmacia). The ligation mix was used to
transform E, coli strain DHI. Recombinant colonies were
identified by in situ hybridization with radiolabeled
cDNA prepared by random priming of reverse transcription
WO 91/02752 PCT/CA90/00252
'~C.'~'~3 ~~3 i
-32-
of virion genomic RNA or random priming cDNA synthesis
with the Klenow fragment of DNA polymerise I utilizing
denatured restriction fragments as template.
Northern Blotting
Total cellular RNA was extracted from
BCV-infected MDBK cells 18 hrs after infection.
Infected cells were lysed in 20 mM tris-HC1, pH 8.0, 50
mM KC1, 5 mM MgCl2 containing 1% NP-40 and 0.5% sodium
deoxycholate. After brief vortexing and centrifugation
at 12,000 xg for 1 min, the supernatant was extracted
with phenol: chloroform:isoamyl alcohol and ethanol
precipitated. Poly A+ RNA was selected by oligo-DT
cellulose chromatography (Aviv et al., (1972) Proc.
Natl. Acid. Sci. 69:1408). RNA was electrophoresed on
1~ formaldehyde-agarose gels (Lehrach et al., (1977)
Biochemistry 16:4743-4748) and electroblotted onto
Zeta-Probe membrane (Biorad). Radiolabeled probes were
prepared as described above and hybridization was
carried out following the manufacturer's directions.
DNA Sequencing
cDNA clones representing the E2 and E3 genes
of BCV in plasmid pTZ 19R were sequenced using the
dideoxy chain termination method (Singer et al., (1977)
Proc. Natl. Acid. Sci. 74:5463-5467) after generation of
an extensive series of overlapping deletions (Henikoff
et al., (1984) Gene 28:351-359).
In Vitro Transcription and Translation
Expression constructs of the BCV E2 gene were
prepared by exonuclease III digestion to remove flanking
WO 91/02752 PCT/CA90/00252
i~~~~~~ 7
-33-
cDNA sequences (Henikoff et al., supra). BCV E2
sequences extending from nucleotide 6 to 4129 and E3
sequences from nucleotide 10 through 1305 were s-ubcloned
into the BamHI site of pTZ 19R. After EcoRI digestion,
m7GpppA-capped transcripts were synthesized with T7 RNA
polymerase (Melton et al., (1984) Nuc. Acids Res.
12:7035-7056) and translated in rabbit- reticulocyte
extracts containing 600 uCi/ml 35S-methionine (Amersham,
>800 Ci/mmole). The products were immunoprecipitated
with pooled monoclonal antibodies described by Deregt et
al., (1987) Virolocty 161:410-420, electrophoresed on 13%
acrylamide:DATD (30:1.4) gels according to Laemmli
(1970) Nature (London) 227:680-685) and fluorographed.
Construction of E2 and E3 Clones and Expres-
sion in Insect Cells by Recombinants of
AutoQrapha californica baculovirus
Because clones pCVAI2H and pCVAI2I contained
partially overlapping segments of the E2 gene, a single
clone containing the entire E2 gene was constructed by
fusing the 5' BamHI-PstI fragment from pCVAI2H to the 3'
PstI-BamHI fragment of pCVAI2I. Noncoding sequences
were removed from the 5' end of the construct by
exonuclease I digestion and addition of a BamHI linker.
Noncoding sequences were removed from the 3' end of the
gene by partial digestion with TaqI and addition of a
BamHI linker. The resulting sequence is shown in FIG.
3.
The expression construct of E3 was constructed
by exonuclease III treatment of the 3' end of pCVAI2H to
a point 51 nucleotides downstream from the initiation
codon of the E2 gene. The 5' end of pCVAI2H was
WO 91/02752 PCT/CA90/00252
2~~6u »'~5
-34-
digested with MboII, and BamHI linkers were added.
Therefore, the final gene construct begins 8 nucleotides
upstream of the E3 initiation codon and~terminates 51
nucleotides into the E2 gene.
The gene constructs were then subcloned in
baculovirus transfer vector pVL941 and inserted into the
genome of A. californica baculovirus by homologous
recombination. Recombinant viruses were identified by
plaque hybridization and several rounds of plaque
purification.
Monolayers of Spodoptera fruQiperda cells
(SF9) were infected with the recombinant baculoviruses
and incubated at 28°C. At the times indicated, the
medium was replaced with methionine-free Grace's medium
containing 50 uCi/ml of 35S-methionine for 2 hours. The
cells were collected and lysed in RIPA buffer. The
radiolabeled products were immunoprecipitated with
monoclonal antibody and analyzed by SDS-polyacrylamide
gel.
Expression of BCV Genome
Expression constructs of the BCV E2 gene were
prepared by exonuclease III digestion to remove flanking
cDNA sequences (Heinkoff, supra). BCV E2 sequences
extending from nucleotide 6 to 4129 and E3 sequences
extending from nucleotide 10 through 1305 were subcloned
into the baculovirus transfer vectors PYMI and pVL941,
respectively (Matsura, Y., et al. (1987) J. Gen. Virol.
68:1233-1250 and Summers, M.D. and G.E. Smith (1987)
Texas Agricultural Experiment Station Bulletin 1555).
The genes were then inserted into the genome of the
baculovirus Auto4ra~ha californica by homologous
WO 91/02752 PCT/CA90/00252
2~~s~~~; i
-35-
recombination. Recombinant viruses were identified by
plaque hybridization and serial plaque purification.
Spodoptera fruQiperda cells were infected with the
plaque purified recombinant viruses and incubated at
28°C for 36 hours. The media was removed and replaced
with Grace's medium lacking methionine containing 50
uCi/ml 35S-methionine (Amersham, >800 Ci/mMole) and
incubated an additional 2 hours. The cells were scraped
into phosphate-buffered saline and pelleted at 1000 x g
for one minute and lysed in RIPA buffer containing 1%
NP-40 and 1% sodium deoxycholate. Nuclei and insoluble
material were removed by centrifugation at 15,000 x g
for 5 minutes and the recombinant polypeptides were
immunoprecipitated with monoclonal antibodies. The
precipitated products were analyzed by electrophoresis
on 10% polyacrylamide gels (Laemmli (1970) Nature
(London) 227:680-685) and fluorography.
Characterization of the Polypeptide Products
of the BCV E2 and E3 Genes
In order to demonstrate directly that the
cloned sequences represented the genes for the BCV E2
and E3 genes, the sequences shown in FIGS. 3 and 4 were
subcloned in the AutoQrapha californica baculovirus and
expressed in insect cells.
Expression of the BCV E3 gene in insect cells
yielded a polypeptide of approximately 120K when
analyzed in the absence of 2-mercaptoethanol. Addition
of 2-mercaptoethanol to the immunoprecipitated product
prior to electrophoresis dissociated the 120K product to
a monomeric 56K polypeptide. The ability of E3-specific
monoclonal antibodies to specifically precipitate the
-36- _ 206 53fi5
product and its electrophoretic mobility in the presence
and absence of 2-mercaptoethanol demonstrate that the
cloned sequence does represent the gene for the BCV E3
polypeptide.
Expression of the BCV E2 gene in insect cells
and immunoprecipitation with E2-specific monoclonal
antibodies yields a product of approximately 200K. A
similar 200K polypeptide which represents the uncleaved
form of the E2 polypeptide is also detected in BCV
infected mammalian cell lines. Trypsin treatment of
insect cells expressing the BCV E2 gene also results in
cell fusion, a characteristic property of cells
expressing the BCV E2 protein.
Results
Isolation of cDNA Seguences Representing the BCV E2 Gene
Restriction mapping of cloned cDNA inserts
initially resulted in a linear map representing
approximately 4,000 nucleotides of the BCV genome, as
shown for clone pCVAl2 (FIG. 1). In order to determine
the proximity of these sequences to the 3' end of the
virion genome, electrophoretically resolved preparations
of poly(A)+ RNA from BCV infected MDBK cells were probed
with sequences from the 3' end of pCVAl2 (solid box in
FIG. 1). Since coronavirus mRNAs form a 3' nested set
(Stern DF, Kennedy SIT (1980) Coronavirus multiplication
strategy. II Mapping the avian infectious bronchitis
virus intracellular RNA species to the genome. J.
Virology 36:440-449), a probe homologous to the 3'
end of the viral genome hybridizes to all of the viral
mRNAs detected with a probe representative of the entire
genome. To produce the Northern blot in FIG. 2, total
intracellular RNA was extracted from BCV-infected MDBK
cells 18 hours post-infection. Viral genome RNA was
206 5365
-37-
extracted from purified virus. RNA was electrophoresed
on 1~ formaldehyde-agarose gels and electroblotted onto
Zeta Probe*membrane. Hybridization was in 50~
formamide, 5 x SSC at 42°C. Lanes 1, 3, BCV-infected
MDBK intracellular RNA; lane 3, viral genomic RNA.
Probes: lanes 1 and 2, 3' portion of pCVAl2 indicated
in Figure 1; lane 3, clone pCVAI2H. As shown in FIG. 2,
lane 1, radiolabeled cDNA representing the 3' end of
clone pCVAl2 hybridized to 8 species of intracellular
~A~ numbered mRNA 1 through 8, which have been detected
with cDNA probe representative of the entire viral
genome. The origin of the numerous small RNA species is
unknown but might represent intermediates of trans-
cription or replication as described in MHV-infected
cells (Baric et al., (1987) Virology 156:342-354). RNA
1, which may direct the synthesis of nonstructural
(polymerase?) polypeptides, corresponds to the viral
genome RNA (FIG. 2, lane 2). RNAs 5 through 8 direct
the synthesis of 14K NS, lOK NS, matrix (E1) and the
nucleocapsid protein (N) respectively (Lapps et al.,
(1987) Virology 157:47-57). Additional restriction
mapping of pCVAl2 and comparison with the sequences at
the 3' end of the viral genome recently reported (Lapps
et al. su ra), showed that clone pCVAl2 represents
sequences at or very near the 3' end of the genome and
extends approximately 4000 nucleotides upstream (FIG.
1).
Based upon the molecular weight of the BCV E2
precursor of approximately 190K (Deregt et al. supra),
it was predicted that RNA 4 was the only mRNA likely to
contain sufficient unique sequences to encode the BCV E2
polypeptide. In order to identify clones which
*Trademark
WO 91/02752 PCT/CA90/00252
i~~6 ~~~i~..r7
-38-
hybridize only to mRNA 1-4 and may thereby represent the
E2 gene, approximately 25,000 colonies were probed with
the 5' end of clone pCVAl2 (cross-hatched in FIG. 1).
As shown in FIG. 2, lane 3, a series of clones,
represented by pCVAI2H hybridized only to mRNA 1 through
4. Sequencing of the cDNA insert from pCVAI2H and the
overlapping 5' portion of pCVAI2I identified a single
open reading frame of 4089 nucleotides. Based upon a
comparison to the sequence of the E2 gene of MHV-JHM
(Schmidt et al., (1987) J. Gen. Virol. 68:47-56) and
hydropathic analysis (Kyte et al., (1982) J. Mol. Biol.
157:105-132) of the predicted gene product, the
nucleotide sequence shown in FIG. 3 represents the
complete sequence of the BCV E2 gene.
The sequence shown in FIG. 3 extends 14
nucleotides upstream from the E2 initiation codon and
abuts the termination codon for another upstream open
reading frame (see below). Immediately preceding the
ATG of E2 is the conserved heptanucleotide sequence
TCTAAAC similar to the intergenic regions upstream of
the BCV M and N genes except that the conserved
sequences begin 10 and 14 nucleotides upstream of the M
and N genes, respectively (Lapps et al., supra).
The predicted polypeptide product of the BCV
E2 gene is 1363 amino acids long and has a molecular
weight of 150K exclusive of glycosylation. There are 21
potential N-linked glycosylation sites, 11 in the
.proposed S1 subunit and 10 in the S2 subunit, however,
it is not known how many of these sites are
glycosylated.
Immediately following the initiation codon, an
extremely hydrophobic stretch of 15 amino acids may
WO 91/02752 PCT/CA90/00252
;~~s~~s
-39-
function as the signal sequence to direct transport of
the nascent E2 polypeptide across the membrane of the
rough endoplasmic reticulum. Another region of extreme
hydrophobicity is near the carboxy terminus of S2, which
may serve to anchor the S1/S2 dimer of the large -
peplomer into the virion envelope.
Characterization of the E3 Gene
Bovine coronavirus contains a second surface
glycoprotein, E3, which is unique to mammalian
coronaviruses which exhibit hemagglutinating activity.
Based upon a molecular weight of 59K for the mature
polypeptide (Deregt et al., su ra), inspection of the
Northern blot in FIG. 2, lane 1, there are 3 mRNA in
coronavirus-infected cells to which a polypeptide
product have not been assigned. RNA 1 in FIG. 1 is
identical to the virion genome and appears to have
unique sequence in great excess of that necessary to
encode the E3 polypeptide assuming that E3 is not
derived by cleavage of a higher molecular weight
precursor. No such precursor has been reported. RNAs 2
and 3 appeared to have adequate unique sequence such
that either of these two RNAs could direct the synthesis
of E3. The nested nature of coronavirus mRNA suggested
that the sequences unique to mRNA 3 were present
immediately 5' to the gene for E2 in clone pCVAI2H. The
sequence of the 1500 nucleotides at the 5' end of
pCVAI2H was determined and found to contain an open
reading frame of 1272 nucleotides terminating 14
nucleotides upstream of the E2 initiation codon and
encoding a polypeptide of 424 amino acids (FIG. 4). As
shown for the other genes of BCV, the gene is also
WO 91/02752 PCT/CA90/00252
-40-
preceded by the characteristic heptanucleotide ACTAAAC,
beginning 16 nucleotides upstream from the probable
initiation codon.
Hydrophobicity analysis of the predicted
polypeptide product of the unique sequences of mRNA 3
indicated that the polypeptide has the characteristics
of a membrane glycoprotein. Immediately following the
initiation codon is a stretch of 15 hydrophobic amino
acids which may be the signal for translocation of the
9lycoprotein across the membranes of the rough
endoplasmic reticulum. Comparison of this amino acid
sequence with the predicted amino terminal sequence of
E2 shows that 5 of the first 6 amino acids are
identical. Previous experiments have shown that the E3
of BCV is glycosylated by a tunicamycin-sensitive
mechanism (Deregt et al., supra) and the predicted
polypeptide has 9 possible sites for the addition of
N-linked oligosaccharides. The carboxy terminus of the
polypeptide also has an extremely hydrophobic sequence
which may serve to anchor the polypeptide in the virion
envelope.
Characterization of the Polypeptide Products
Produced from the Cloned BCV E2 and E3 Genes
Plasmid
In order to demonstrate directly that the
cloned E2 sequence and the gene immediately adjacent 5'
to the E2 gene are the genes for the peplomer and E3
polypeptides, respectively, the sequences shown in
Figures 3 and 4 were subcloned into plasmid pTZ 19R and
transcribed in vitro. To produce the results shown by
WO 91 /02752 PCT/CA90/00252
-41-
the SDS-PAGE gel in FIG. 5, BCV E2 and E3 cDNA clones
were transcribed in vitro and translated in rabbit
reticulocyte lysates. After immunoprecipitation.with
monoclonal antibodies, the products were analyzed by
SDS-polyacrylamide gel electrophoresis on 13~
acrylamide:DATD gels.
In vitro translation of the E2 gene
transcripts yielded four polypeptides of 29K, 44K, 50K
and 55K which were immunoprecipitated with E2 specific
monoclonal antibodies (Figure 5, lane 1). The products
are similar to those obtained by in vitro translation of
poly A+ mRNA from BCV-infected cells (not shown),
indicating that the 'ow molecular weights are probably
due to the difficulty in translating the large E2 mRNA
in vitro.
In vitro translation of transcripts of the
cloned E3 gene and immunoprecipitation with E3 specific
monoclonal antibodies yields a polypeptide of 45K
(Figure 5, lane 3), as predicted based upon the
nucleotide sequence of the cDNA clone shown in Figure 4.
Baculovirus
In order to demonstrate directly that the
cloned sequences represented the genes for the BCV E2
and E3 polypeptides, the sequences shown in FIGS. 3 and
4 were also subcloned into the A. californica
baculovirus genome and expressed in insect cells.
To produce the result shown in FIG. 6,
recombinant AcNPV-infected cells were radiolabeled as
indicated and immunoprecipitated with E3-specific
monoclonal antibodies prior to elecrophoresis on 10~
SDS-polyacrylamide gels. Lanes A-C show unreduced forms
WO 91/02752 PCT/CA90/00252
;Z~D~~:~'6 i
-42-
of E3 produced in BCV-infected MDBK cells,
BLVE3-infected Sf9 cells, and BAE3S-infected Sf9 cells,
respectively. Lanes D-F show forms as in A-C after
reduction with 2-mercaptoethanol. FIG. 6 also shows
pulse-chase analysis of Sf9 cells producing recombinant
E3 polypeptide. Lane G shows E3 polypeptides after
2-hour label. Lane H shows cell-associated BVLE3
products after 12-hour chase. Lane I shows
immunoprecipitation of media from BVLE3-infected cells
after 12-hour chase. Lane J shows cell-associated
products of BAE3S-infected Sf9 cells after 2-hour label.
Lane K shows cell-associated products of BAE3S-infected
Sf9 cells after 12-hour chase. Lane L shows
immunoprecipitation of media from BAE3S-infected Sf9
cells after 12-hour chase. Lanes M and N show dimeric
forms from BAE3S-infected cells and media, respectively,
after 12-hour chase.
To produce the results shown in FIG. 7, cells
were infected with baculovirus recombinants at a
multiplicity of 5. At 40 hours post-infection, the
cells were radiolabeled for one hour with 100 uCi/ml
35S_methionine. The cells were harvested and lysed in
RIPA buffer, and total cell extracts were analyzed by
electrophoresis on 7.5~ polyacrylamide gels. Panel A
presents an analysis of whole cell lysates. Lane 1,
shows uninfected cells. Lane 2, shows _A.
californica-infected cells. Lanes 3-6 show cells
infected with recombinants AcE2A, -B, -C, and -D,
respectively. Panel B presents immunoprecipitated
Products, as in Panel A. Arrows indicate the positions
of the 180 kDa E2 and 145 kDa E2c (c=core, or
unglycosylated) polypeptides.
. 206 5365
-43-
Expression of the BCV E3 gene in insect cells
yielded a polypeptide of approximately 56 K which is
immunoprecipitated with E3-specific monoclonal
antibodies, as shown in FIG. 6. The polypeptide
migrates slightly more rapidly than the authentic
protein from purified HCV virions. The ability of
monoclonal antibodies to specifically immunoprecipitate
the polypeptide proves the identity of the polypeptide
and indicates that the recombinant protein is
immunologically identical to the native viral
polypeptide.
Expression of the E2 polypeptide in insect
cells, as shown in FIG. 7, yields two polypeptides of
approximately 180K and 145K which are immunoprecipitated
bY monoclonal antibodies specific for the E2 polypeptide
of bovine coronavirus. Tunicamycin treatment of the
insect cells results in a decrease of the 180K product
with an increase in the 145K product which demonstrates
that the 145K polypeptide is a nonglycosylated form of
the E2 polypeptide.
At the amino acid sequence level, there is
some similarity between murine hepatitis virus strains
JHIrt, A59, and bovine coronavirus E2 glycoproteins
(Schmidt I, Skinner M, Siddell S (1987) Nucleotide
sequence of the gene encoding the surface projection
glycoprotein of Coronavirus MHV-JHM. J. Gen. Virology
68:47-56); (de Groot RJ, Maduro J, Lenstra JA, Horzinek
MC, Van der Zeijst BAM, Spaan WJM (1987) cDNA cloning
and sequence analysis of the gene encoding the peplomer
protein of feline infectious peritonitis virus. J. Gen.
Virology 68:2639-2646). The amino acid sequences of the
bovine coronavirus and murine hepatitis virus E2
glycoproteins and our calculations on the degree of
homology as shown in FIG. 8. Sequences are aligned to
show maximum homology. Upper case letter indicates a
conserved residue at that specific position. Each
hyphen "-" means a gap of one residue has been
introduced in order to maximize homology. In each case,
WO 91/02752 PCT/CA90/00252
2 ~ 6 ~ ~ ~ ~ -44-
the BCV sequence is the top line. Amino acid numbers at
the beginning of each line are noted at the left margin.
In the plot shown, conservative changes are.
considered as nonhomologous. At this stringency,
MHV-JHM is 69.1% homologous to BCV and A59 is 67.7%. At
a lower stringency in which the following substitutions
are considered conservative, S=T, K=R, F=L=M=I=V, H=Y=W,
A=C, the homologies increase to 75.5 and 73.9%,
respectively.
These values completely ignore the fact that
BCV contains additional sequence which is not
represented in the other two viruses. If the additional
sequence in BCV is considered in the comparison, the
values decrease to 62.7 and 67.7% under a high
stringency comparison and 68.4 and 71.8% under
conditions in which the conservative substitutions are
considered as homologous.
Deposit of Biological Materials
The following materials were deposited with
the American Type Culture Collection (ATCC), 12301
Parklawn Drive, Rockville, Maryland 20852, U.S.A.
These deposits will be maintained under the terms of the
Budapest Treaty on the deposit of microorganisms. The
nucleotide sequences of the deposited materials are
incorporated by reference herein, as well as the
sequences of the polypeptides encoded thereby. In the
event of any discrepancy between a sequence expressly
disclosed herein and a deposited sequence, the deposited
sequence is controlling. The deposit of such material,
or its availability, is not the grant of a license to
make, use, or sell any of the deposited materials.
WO 91 /02752 . PCT/CA90/00252
X206 5365
-45-
Material ATCC Accession No. Deposit Date
pT18E3 (E. coli JM105) 68040 29 June 1989
pT18E2 (E. coli JM105) 68041 - 29 June 1989
While the present invention has been
illustrated above by certain specific embodiments, the
specific examples are not intended to limit the scope of
the invention as described in the appended claims.
15
25
